"Over the course of this critical year, we hope to launch as many as four new medicines for challenging diseases, while ...
Hims & Hers is bouncing back after a brutal selloff, yet the legal heat keeps rising and its two biggest drug suppliers are ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Revenue jumped nearly 49%, yet Hims & Hers investors fled anyway. Behind the selloff sit shrinking margins, a subscriber slip ...
Eli Lilly has a deep pipeline beyond GLP-1 products that could support strong sales and earnings growth over the long term ...
・UBS said Lilly’s underlying momentum and a higher Q4 growth run rate could potentially make current estimates appear too conservative. ・AbbVie’s Q3 revenue rose 10.3% to $17.40 billion, driven by ...
Quick ReadHims & Hers stock plunged 26% in a week after Q3 results showed the branded GLP-1 pivot crushing gross margin to 57 ...
Hims & Hers (NYSE:HIMS) is expected to release third-quarter earnings today at 4:05 PM ET. Shares are down 28.36% ...